| Biomarker ID | 477 |
| PMID | 19854473 |
| Year | 2010 |
| Biomarker | PHD1 (prolyl-4-hydroxylases 1) |
| Biomarker Basis | Expression Based |
| Biomolecule | Protein |
| Source | Cell Lines |
| Subjects | Humans |
| Regulation | Increased expression in Biochemical Recurrence |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways Include:-HIF-2-alpha transcription factor network,Cellular response to hypoxia,Hypoxic and oxygen homeostasis regulation of HIF-1-alpha, Renal cell carcinoma,Pathways in cancer |
| Experiment | PSA recurrence Vs No PSA recurrence |
| Type of Biomarker | Prognostic |
| Cohort | Prostate cancer cell lines PC3 and DU145 were used for the analysis |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p <0.001 |
| Method Used | Immunohistochemistry |
| Clinical | No |
| Remarks | Univariate Analysis. Accumulation of PHD-1 especially in the nucleus, is a significant indicator for a worse prognosis |
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on human patient cohort; Results on statistically significant |
| Technical Name | EGLN2 |